![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AETERNA ZENTARIS ADVANCES AN-152 TARGETED ANTICANCER AGENT INTO CLINICAL DEVELOPMENT
AETERNA ZENTARIS ADVANCES AN-152 TARGETED ANTICANCER AGENT INTO CLINICAL DEVELOPMENT
AEterna Zentaris has initiated a company-sponsored Phase I dose-ranging study for its targeted anticancer agent AN-152.
AN-152 is a novel cytotoxic conjugate that has the potential to selectively and specifically target certain types of cancer cells that express Luteinizing Hormone Releasing Hormones (LHRH) receptors and thereby may offer a better safety and efficacy profile as compared to the cytotoxic agent alone.
The Phase I study, which will be conducted at university clinics in Gottingen and Frankfurt/Main in Germany, will evaluate the safety (including maximum-tolerated dose and dose-limiting toxicity) and pharmacokinetics of intravenously administered AN-152 in patients with LHRH receptor positive ovarian, endometrial or breast cancer. A high percentage of these cancers, in addition to hormone-refractory prostate cancer, are known to be LHRH receptor positive and, therefore, represent logical initial indications for AN-152.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct